Filing Flows › Guardant Health (GH) › Stock forecast & fair value
Guardant Health (GH) stock forecast and fair value
Guardant Health (GH) trades at $150.87. 25 analysts' median price target is $200.00 (+33%), from $105.00 to $240.00. Across 16 valuation methods the middle fair value is $21.05 (-86%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| EV/Sales vs peers | $22.56 | $39.36 | $77.09 | -74% |
| EV/Sales vs peers, weighted | $16.17 | $21.89 | $63.40 | -85% |
| Sum of the parts (segments × peer EV/Sales) | $22.93 | $43.22 | $85.40 | -71% |
| Sum of the parts, weighted (segments × weighted peer EV/Sales) | $34.28 | $54.52 | $86.39 | -64% |
| Analysts' price targets | $105.00 | $200.84 | $240.00 | +33% |
| Shareholder yield (dividends + buybacks) | $3.89 | $4.39 | $5.03 | -97% |
| Path-to-margin DCF | −$11.40 | −$0.64 | $10.02 | -100% |
| Path-to-margin DCF, dilution-adjusted | −$10.81 | −$0.62 | $9.77 | -100% |
| Exit-multiple (venture) method | $14.27 | $21.05 | $41.30 | -86% |
| EV/Sales vs Rule of 40 (all-company fit) | $2.63 | $13.38 | $42.87 | -91% |
Guardant Health's latest quarter
Guardant Health, Q3 2026: revenue $361M (+36% year over year), operating margin -36.8%, net loss $124M, operating cash flow −$23.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for GH stock?
The median of 25 analysts' 12-month targets is $200.00, +33% from $150.87; the range is $105.00 to $240.00. The average rating is strong buy.
What is Guardant Health's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between −$0.64 and $200.84, with a middle value of $21.05 against a price of $150.87. Each method's assumptions are on the page.
Does Guardant Health usually beat earnings estimates?
It beat the consensus EPS estimate in 60% of the quarters on record.
Is GH stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.